JCOG1018: Rp3 Study in Elderly Patients with MEtastatic CRC as 1st-line Tx
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2614012
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Arm A: 5-FU/LV or CAP + BEV
1. 5-FU/l-LV (msDG) + BEV
(1) BEV: 5 mg/kg, iv, day 1
(2) l-LV: 200 mg/m2, iv, day 1
(3) 5-FU: 2,400 mg/m2/46 hr, civ, day 1-3
2. CAP + BEV
[ 50 mL/min <= Ccr ]
(1) BEV: 7.5 mg/kg, iv, day 1
(2) CAP: 1,250 mg/m2, oral, twice a day, day 1-14
[ 30 mL/min <= Ccr<50 mL/min ]
(1) BEV: 7.5 mg/kg, iv, day 1
(2) CAP: 1,000 mg/m2, oral, twice a day, day 1-14
Arm B: 5-FU/LV or CAP + L-OHP + BEV
1. mFOLFOX7 + BEV
(1) BEV: 5 mg/kg, iv, day 1
(2) l-LV: 200 mg/m2 + L-OHP:85 mg/m2, iv, day 1
(3) 5-FU: 2,400 mg/m2/46 hr, civ, day 1-3
2. CAPOX + BEV
[ 50 mL/min <= Ccr ]
(1) BEV: 7.5 mg/kg, iv, day 1
(2) l-LV: 130 mg/m2, iv, day 1
(3) CAP: 1,000 mg/m2,oral, twice a day, day, day 1-14
[ 30 mL/min <= Ccr < 50 mL/min ]
(1) BEV: 7.5 mg/kg, iv, day 1
(2) L-OHP: 130 mg/m2, iv, day 1
(3) CAP: 750 mg/m2, oral, twice a day, day 1-14
Primary outcome(s): Progression-free survival
Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose
创建时间：
2012-09-15
